Cart
sales@molnova.com
ACT-389949
CAS No. 1258417-54-7
ACT-389949( —— )
Catalog No. M23429 CAS No. 1258417-54-7
ACT-389949 is a potent and selective agonist of formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX), with an EC50 of 3 nM for FPR2/ALX internalization into monocytes.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 140 | In Stock |
|
| 10MG | 215 | In Stock |
|
| 25MG | 377 | In Stock |
|
| 50MG | 551 | In Stock |
|
| 100MG | 826 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameACT-389949
-
NoteResearch use only, not for human use.
-
Brief DescriptionACT-389949 is a potent and selective agonist of formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX), with an EC50 of 3 nM for FPR2/ALX internalization into monocytes.
-
DescriptionACT-389949 is a potent and selective agonist of formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX), with an EC50 of 3 nM for FPR2/ALX internalization into monocytes. It has the potential for the treatment of inflammatory disorders.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorFPR2/ALX
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1258417-54-7
-
Formula Weight428.39
-
Molecular FormulaC20H18F2N6O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mg/mL (23.34 mM; ultrasonic and adjust pH to 1 with HCl)
-
SMILESO=C(NC1=NN(N=C1)CC2=NC(C(F)(C)F)=CO2)C3=C(OC(C)=N3)C4=CC=CC(C)=C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Stalder AK,et al. Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949. Br J Clin Pharmacol. 2017 Mar;83(3):476-486.
molnova catalog
related products
-
Glucocapparin
The herbs of Capparis spinosa L.
-
[Sar1, Ile8]-Angiote...
[Sar1, Ile8]-Angiotensin II is a peptide that has multiple effects on vascular smooth muscle, including contraction of normal arteries and hypertrophy or hyperplasia of cultured cells or diseased vessels. The biological activities of angiotensin II antagonists upon basal and angiotensin II-stimulated aldosterone production were evaluated in an isolated canine glomerulosa cell preparation.
-
RI-STAD 2
AKAP disruptor. Selectively binds PKA-RI with high affinity (KD values are 6.2 and 12.1 nM for the RIα and β subunits, respectively) and blocks its interaction with AKAP. Inhibits type I PKA-mediated phosphorylation in live cells. Cell permeable.
